Diagnostic performance of gadoxetic acid-enhanced abbreviated magnetic resonance imaging protocol in small hepatocellular carcinoma (≤2 cm) in high-risk patients
Restricted accessResearch articleFirst published online October, 2023
Diagnostic performance of gadoxetic acid-enhanced abbreviated magnetic resonance imaging protocol in small hepatocellular carcinoma (≤2 cm) in high-risk patients
Biannual Ultrasound showed insufficient sensitivity in detecting small or early-stage hepatocellular carcinoma (HCC). Abbreviated magnetic resonance imaging (A-MRI) protocols with fewer sequences demonstrated higher HCC detection sensitivity than ultrasound with acceptable cost and examination time.
Purpose
To compare the diagnostic performance of gadoxetic acid-enhanced A-MRI with a full sequence MRI (F-MRI) protocol for small HCC (≤2 cm) in cirrhotic or hepatitis B virus-infected high-risk patients.
Material and Methods
Two hundred and four consecutive patients with 166 pathologically confirmed small HCC who underwent preoperative gadoxetic acid-enhanced MRI were retrospectively included. A-MRI set comprised T1-weighted hepatobiliary phase imaging, T2-weighted imaging, diffusion-weighted imaging and apparent diffusion coefficient mapping. Two independent radiologists blinded to clinical data assessed the A-MRI set and F-MRI set. Per-patient HCC and per-lesion HCC diagnostic performance were compared.
Results
Per-patient HCC detection sensitivity of A-MRI set was 93.8% and 91.2% for observer 1 and observer 2, and, for the F-MRI set, the per-patient HCC detection sensitivity was 96.6% and 95.2%, respectively. There was no significant difference in per-patient sensitivity, specificity and per-lesion HCC detection sensitivity between the two imaging sets for both readers. (P = 0.06–0.25) The A-MRI set showed higher sensitivity on HCC without arterial phase hyperenhancement, and the F-MRI set demonstrated with higher sensitivity on HCC with arterial phase hyperenhancement (P < 0.05).
Conclusion
A-MRI using diagnostic criteria including hypointensity on hepatobiliary phase plus mild to moderate hyperintensity on T2-weighted imaging or restricted diffusion demonstrated comparable sensitivity and specificity for small HCC compared to the F-MRI protocol in high-risk patients.
SungHFerlayJSiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2021;71:209–249.
2.
OzakyolA. Global epidemiology of hepatocellular carcinoma (HCC epidemiology). J Gastrointest Cancer2017;48:238–240.
3.
AkinyemijuTAberaS, et al.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol2017;3:1683–1691.
4.
MarreroJAKulikLMSirlinCB, et al.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology2018;68:723–750.
5.
OmataMChengALKokudoN, et al.Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int2017;11:317–370.
6.
EASL Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol2018;69:182–236.
7.
ZhangBHYangBHTangZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol2004;130:417–422.
8.
ColliAFraquelliMCasazzaG, et al.Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol2006;101:513–523.
9.
TzartzevaKObiJRichNE, et al.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology2018;154:1706–1718.e1.
10.
AyusoCRimolaJVilanaR, et al.Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol2018;101:72–81.
11.
HeimbachJKKulikLMFinnRS, et al.AASLD Guidelines for the treatment of hepatocellular carcinoma. Hepatology2018;67:358–380.
12.
LivraghiTMeloniFDi StasiM, et al.Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?Hepatology2008;47:82–89.
13.
KimSYAnJLimYS, et al.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol2017;3:456–463.
14.
BesaCLewisSPandharipandePV, et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY2017;42:179–190.
15.
MarksRMRyanAHebaER, et al.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid–enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol2015;204:527–535.
16.
TillmanBGGormanJDHruJM, et al.Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clin Radiol2018;73:485–493.
17.
Vietti VioliNLewisSLiaoJ, et al.Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. Eur Radiol2020;30:6003–6013.
18.
AnJYPeñaMACunhaGM, et al.Abbreviated MRI for hepatocellular carcinoma screening and surveillance. RadioGraphics2020;40:1916–1931.
19.
YokooTMasakiNParikhND, et al.Multicenter validation of abbreviated MRI for detecting early-stage hepatocellular carcinoma. Radiology2023;307:e220917.
20.
KohDMBa-SsalamahABrancatelliG, et al.Consensus report from the 9th international forum for liver magnetic resonance imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol2021;31:5615–5628.
21.
EfremidisSCHytiroglouPMatsuiO. Enhancement patterns and signal-intensity characteristics of small hepatocellular carcinoma in cirrhosis: pathologic basis and diagnostic challenges. Eur Radiol2007;17:2969–2982.
22.
SanoKIchikawaTMotosugiU, et al.Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid–enhanced MR imaging. Radiology2011;261:834–844.
23.
WeiYYeZYuanY, et al.A new diagnostic criterion with gadoxetic acid-enhanced MRI may improve the diagnostic performance for hepatocellular carcinoma. Liver Cancer2020;9:414–425.
24.
KudoMZhengRQKimSR, et al.Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. INT2008;51:17–26.
25.
KimYKLeeWJParkMJ, et al.Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology2012;265:104–114.
26.
HyodoTMurakamiTImaiY, et al.Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology2013;266:480–490.
27.
ChoiMHChoiJILeeYJ, et al.MRI Of small hepatocellular carcinoma: typical features are less frequent below a size cutoff of 1.5 cm. AJR Am J Roentgenol2017;208:544–551.
28.
ChenCZRaoSXDingY, et al.Hepatocellular carcinoma 20 mm or smaller in cirrhosis patients: early magnetic resonance enhancement by gadoxetic acid compared with gadopentetate dimeglumine. Hepatol Int2014;8:104–111.
29.
ChoiSHByunJHLimY-S, et al.Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. J Hepatol2016;64:1099–1107.
30.
KimDHChoiSHShimJH, et al.Meta-analysis of the accuracy of abbreviated magnetic resonance imaging for hepatocellular carcinoma surveillance: non-contrast versus hepatobiliary phase-abbreviated magnetic resonance imaging. Cancers (Basel)2021;13:2975.
31.
ParkSHKimBKimSY, et al.Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: lI-RADS validation in a HCC-screening cohort. Eur Radiol2020;30:2302–2311.
32.
AubéCObertiFLonjonJ, et al.EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int2017;37:1515–1525.
33.
ChoiJYLeeJMSirlinCB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology2014;272:635–654.
34.
KwonHJByunJHKimJY, et al.Differentiation of small (≤2 cm) hepatocellular carcinomas from small benign nodules in cirrhotic liver on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance images. Abdom Imaging2015;40:64–75.
35.
ParkMJKimYKLeeMW, et al.Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology2012;264:761–770.
36.
ParkMSKimSPatelJ, et al.Hepatocellular carcinoma: detection with diffusion-weighted versus contrast-enhanced magnetic resonance imaging in pretransplant patients. Hepatology2012;56:140–148.
37.
KimJEKimSHLeeSJ,et al.Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging. AJR Am J Roentgenol2011;196:W758–W765.
38.
ParkMJKimYKLeeMH,et al.Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (≤ 2.0 cm) in patients with hepatitis-induced liver cirrhosis. Acta Radiol2013;54:127–136.
39.
ParikhTDrewSJLeeVS, et al.Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology2008;246:812–822.
40.
LeeMHKimSHParkMJ, et al.Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol2011;197:W868–W875.
